NEW ORLEANS — The mortality rate of patients with hospital-onset Pseudomonas aeruginosa infection was nearly twice as high among those with multidrug-resistant infections than non–multidrug-resistant ...

PESHAWAR: Tuberculosis (TB) patients with multi-drug resistance (MDR) have stopped visiting treatment centres after incentives offered to them were suspended. Officials privy to the development told ...

Please provide your email address to receive an email when new articles are posted on . Brust and colleagues conducted an observational cohort study of 206 patients in South Africa with ...

Dr Haumschild leads a discussion highlighting goals of therapy and social determinants of health affecting MDR HIV diagnosis and treatment. Ryan Haumschild, PharmD, MS, MBA: Mr Driffin, a question ...

June 30, 2011 (Baltimore, Maryland) — The number of new antibiotics that can be used to treat multidrug-resistant (MDR) Gram-negative infections is dwindling. New antibacterial drugs will not be the ...

With Gift Aid, your generous donation of £10 would be worth £12.50 at no extra cost to you. Yes, I want to Gift Aid any donations made to NAM now, in the future and in the past four years I am a UK ...

On the heels of the news of totally drug-resistant (TDR) TB being identified in India-- and disavowed, unfortunately, by the Indian government-- the World Health Organization has released an update on ...

With Gift Aid, your generous donation of £10 would be worth £12.50 at no extra cost to you. Yes, I want to Gift Aid any donations made to NAM now, in the future and in the past four years I am a UK ...

Daniel Driffin, BS, MPH, provides insights regarding factors influencing patient adherence to multidrug-resistant HIV treatment. Ryan Haumschild, PharmD, MS, MBA: Let’s discuss the major unmet needs, ...

The World Health Organisation (WHO) recently announced "landmark changes" cutting down the treatment time for multi-drug-resistant tuberculosis (MDR-TB) from 18-24 months at present to six months, but ...

FIVE hundred patients of Multi-Drug Resistant Tuberculosis, MDR-TB, are to benefit from quality assured 2nd Line Drugs, valued at US$1.42 million being procured by the Federal government of Nigeria.